Elsevier

Ophthalmology

Volume 123, Issue 12, December 2016, Pages 2628-2630
Ophthalmology

Report
Risk Alleles Associated with Neovascularization in a Pachychoroid Phenotype

Presented in part at the annual meeting of the Macula Society, February 24–27, 2016, Miami, Florida.
https://doi.org/10.1016/j.ophtha.2016.06.060Get rights and content

First page preview

First page preview
Click to open first page preview

Cited by (30)

  • Central serous chorioretinopathy: An update on risk factors, pathophysiology and imaging modalities

    2020, Progress in Retinal and Eye Research
    Citation Excerpt :

    Even though these two entail formation of macular neovascularization they differ from neovascular AMD, both in terms of aetiology and thereby in their management strategies. Moreover, even though patients with AMD and those with pachychoroid neovascularization have been found to have similar genetic profiles with respect to established AMD risk alleles, their frequencies were very low and similar in non-neovascular and neovascular pachychoroid phenotypes (Dansingani et al., 2016b). Focal choroidal excavation (Fig. 13) is defined as a local idiopathic depression in the choroid in patients lacking any systemic cause for choroidal thinning (Obata et al., 2013).

  • Pachychoroid disease

    2019, Central Serous Chorioretinopathy
  • Dilated choroidal vascular channels in pachychoroid neovasculopathy

    2023, Clinical and Experimental Ophthalmology
View all citing articles on Scopus

Financial Disclosure(s): The author(s) have made the following disclosure(s): L.T.P. and S.H.: Employed by Regeneron Inc., with stock options.

R.F.S.: Consultant – Bausch & Lomb and Topcon Corp. (Tokyo, Japan); Royalty fees – Topcon.

J.M.K.: Consultant – Bayer HealthCare.

L.A.Y.: Support – Genentech have funded an educational program on retinal disease.

M.J.C.: Consultant – Bausch & Lomb, Speaker – Genentech, and holds equity in Ohr Pharmaceuticals.

M.E.: Consultant – Bayer HealthCare and Genentech.

K.B.F.: Consultant – Genentech, Bayer HealthCare, Optovue, Heidelberg Engineering, and Optos.

The LuEsther T. Mertz Retinal Research Center and the Macula Foundation Inc., New York, New York, supported this research but had no role in the design or conduct of the study or the decision to publish.

Author Contributions:

Conception and design: Perlee, Hamon, Lee, Shah, Chen, Hewitt, Freund

Data collection: Dansingani, Lee, Shah, Spaide, Sorenson, Klancnik, Yannuzzi, Barbazetto, Cooney, Engelbert, Freund

Analysis and interpretation: Dansingani, Perlee, Hamon, Freund

Obtained funding: Not applicable

Overall responsibility: Dansingani, Perlee, Hamon, Lee, Shah, Spaide, Sorenson, Klancnik, Yannuzzi, Barbazetto, Cooney, Engelbert, Chen, Hewitt, Freund

View full text